Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 5:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–15 of 15 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Respiratory Syncytial Virus Hospitalizations Clear all
Terminated Phase 3 Interventional Results available

A Study of Rilematovir in Infants and Children and Subsequently in Neonates Hospitalized With Acute Respiratory Tract Infection Due to Respiratory Syncytial Virus (RSV)

NCT04583280
View directory record Official record
Conditions
Respiratory Tract Infections
Interventions
Rilematovir, Rilematovir X mg/kg, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
1 Day to 5 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
5
States / cities
Orlando, Florida • Jackson, Mississippi • The Bronx, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Jul 23, 2026, 5:22 AM EDT
Completed Phase 1 Interventional

A Study of ALS-008176 in Infants Hospitalized With RSV

NCT02202356
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
ALS-008176, Placebo
Drug
Lead sponsor
Alios Biopharma Inc.
Industry
Eligibility
Up to 12 Months
Enrollment
183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
17
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Long Beach, California + 14 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2025 · Synced Jul 23, 2026, 5:22 AM EDT
Completed Phase 2 Interventional Results available

A Study to Explore the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of JNJ-53718678 at Two Dose Levels in Non-Hospitalized Adult Participants Infected With Respiratory Syncytial Virus

NCT03379675
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
JNJ-53718678 500 mg, JNJ-53718678 80 mg, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
13
States / cities
Cerritos, California • Chula Vista, California • Garden Grove, California + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Jul 23, 2026, 5:22 AM EDT
Completed No phase listed Observational

Study to Evaluate the Incidence of Hospitalizations and Respiratory Tract Infections in Premature Infants

NCT00384462
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
Not listed
Lead sponsor
MedImmune LLC
Industry
Eligibility
1 Month to 6 Months
Enrollment
346 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
59
States / cities
Birmingham, Alabama • Benton, Arkansas • Jonesboro, Arkansas + 50 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2009 · Synced Jul 23, 2026, 5:22 AM EDT
Completed No phase listed Observational

An Observational Study of Respiratory Syncytial Virus (RSV) Hospitalizations in Preterm Infants

NCT02273882
View directory record Official record
Conditions
Respiratory Syncytial Virus Hospitalizations
Interventions
Not listed
Lead sponsor
AstraZeneca
Industry
Eligibility
Up to 12 Months
Enrollment
497 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
44
States / cities
Little Rock, Arkansas • Loma Linda, California • Long Beach, California + 40 more
Source: ClinicalTrials.gov public record
Updated May 22, 2017 · Synced Jul 23, 2026, 5:22 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

A Study to Learn About the Study Medicine Sisunatovir in Adults With Respiratory Syncytial Virus (RSV) Infection

NCT06079320
View directory record Official record
Conditions
Respiratory Syncytial Virus Infection
Interventions
Sisunatovir, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
14
States / cities
Garden Grove, California • Westminster, California • Miami, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2025 · Synced Jul 23, 2026, 5:22 AM EDT
Completed Phase 2 Interventional Results available

Efficacy, Pharmacokinetics, and Safety of Presatovir in Hospitalized Adults With Respiratory Syncytial Virus (RSV) Infection

NCT02135614
View directory record Official record
Conditions
Respiratory Syncytial Virus Infection
Interventions
Presatovir, Presatovir placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
189 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
9
States / cities
Chicago, Illinois • Annapolis, Maryland • Detroit, Michigan + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2018 · Synced Jul 23, 2026, 5:22 AM EDT
Completed Phase 2 Interventional

A Study of EDP-938 in Non-hospitalized Adults With RSV Who Are at High Risk for Complications.

NCT05568706
View directory record Official record
Conditions
RSV Infection
Interventions
EDP-938, Placebo
Drug
Lead sponsor
Enanta Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
31
States / cities
Tempe, Arizona • Fresno, California • Lomita, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2025 · Synced Jul 23, 2026, 5:22 AM EDT
Completed Not applicable Interventional Results available

A Study to Evaluate a Single Intravenous Dose of Motavizumab for the Treatment of Children Hospitalized With Respiratory Syncytial Virus (RSV) Illness

NCT00421304
View directory record Official record
Conditions
RSV Illness in ≤12 Months of Participants
Interventions
Motavizumab, Placebo
Biological · Other
Lead sponsor
MedImmune LLC
Industry
Eligibility
0 Months to 12 Months
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
26
States / cities
Tucson, Arizona • Long Beach, California • Orange, California + 23 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2021 · Synced Jul 23, 2026, 5:22 AM EDT
Completed No phase listed Observational

Surveillance Study of Respiratory Syncytial Virus Infection (RSV) in Subjects < 24 Months of Age

NCT01754428
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
Not listed
Lead sponsor
Gilead Sciences
Industry
Eligibility
Up to 24 Months
Enrollment
2,432 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
15
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Denver, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2013 · Synced Jul 23, 2026, 5:22 AM EDT
Terminated Phase 1 Interventional

A Study to Assess the Pharmacokinetics, Safety, and Tolerability of Multiple Doses of Orally Administered JNJ-53718678 in Infants Hospitalized With Respiratory Syncytial Virus (RSV) Infection

NCT02593851
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections, Virus Diseases
Interventions
JNJ-53718678, Placebo
Drug
Lead sponsor
Janssen Sciences Ireland UC
Industry
Eligibility
1 Month to 24 Months
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Kirksville, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 5, 2019 · Synced Jul 23, 2026, 5:22 AM EDT
Terminated Phase 2 Interventional Results available

A Study to Evaluate the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of Orally Administered Lumicitabine (JNJ-64041575) Regimens in Hospitalized Infants and Children Aged 28 Days to 36 Months Infected With Respiratory Syncytial Virus

NCT03333317
View directory record Official record
Conditions
Respiratory Syncytial Viruses
Interventions
Lumicitabine, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
28 Days to 36 Months
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
6
States / cities
Long Beach, California • Kansas City, Missouri • Syracuse, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2019 · Synced Jul 23, 2026, 5:22 AM EDT
Completed Phase 2 Interventional

A Phase 2a Study to Evaluate Orally Administered ALS-008176 in Adults Hospitalized With a Respiratory Syncytial Virus

NCT02673476
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
ALS-008176, Placebo
Drug
Lead sponsor
Alios Biopharma Inc.
Industry
Eligibility
50 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
11
States / cities
Eustis, Florida • Hialeah, Florida • Miami, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Jul 23, 2026, 5:22 AM EDT
Withdrawn No phase listed Observational

Analysis of Lung Sounds Collected by RESP Biosensor to Support Decision Making in Monitored Hospitalized Pediatric Patients

NCT05661422
View directory record Official record
Conditions
Pediatric Respiratory Diseases, Asthma, RSV Infection, COVID-19
Interventions
RESP™ Biosensor
Device
Lead sponsor
Strados Labs, Inc.
Industry
Eligibility
4 Years to 17 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Savannah, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 15, 2023 · Synced Jul 23, 2026, 5:22 AM EDT
Terminated Phase 2 Interventional Results available

Study to Evaluate the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of Orally Administered Lumicitabine Regimens in Adult Participants Hospitalized With Respiratory Syncytial Virus

NCT02935673
View directory record Official record
Conditions
Respiratory Syncytial Viruses
Interventions
lumicitabine, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
10
States / cities
Fresno, California • Orange, California • Stanford, California + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2019 · Synced Jul 23, 2026, 5:22 AM EDT